Larimar Therapeutics (LRMR) Cash & Current Investments (2013 - 2026)

Larimar Therapeutics (LRMR) has reported Cash & Current Investments for 14 consecutive years, with $156.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Current Investments rose 12.81% year-over-year to $156.3 million; the trailing twelve-month figure through Jun 2026 stood at $156.3 million (up 12.81% YoY), and the FY2025 full-year result was $136.9 million, down 25.4% from the prior year.
• Cash & Current Investments grew to $156.3 million in Q2 2026 per LRMR's latest filing, from $136.9 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $227.3 million in Q1 2024 and bottomed at $54.9 million in Q2 2022.
• Historically, Cash & Current Investments has averaged $139.1 million across 5 years, with a median of $136.9 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments jumped 116.95% in 2024, then tumbled 38.72% in 2025.
• Over 5 years, Cash & Current Investments stood at $118.4 million in 2022, then retreated by 26.71% to $86.8 million in 2023, then surged by 111.38% to $183.5 million in 2024, then retreated by 25.4% to $136.9 million in 2025, then advanced by 14.19% to $156.3 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $156.3 million, $136.9 million, and $175.4 million for Q2 2026, Q4 2025, and Q3 2025 respectively.